A meta-analysis published in Obesity Research & Clinical Practice in 2026 pooled five randomized controlled trials of tesamorelin, a growth hormone–releasing hormone (GHRH) analogue. The findings are consistent across trials, and in one specific population they are meaningful.

That population is adults with HIV-associated lipodystrophy. It is in the title of the paper. It was the enrollment criterion for every trial pooled. There is no randomized evidence for tesamorelin in anyone else.

If you found this article because you came off a GLP-1 and the weight returned around your middle, read that paragraph again before you read the numbers below. The numbers are real. They were measured in people whose visceral fat accumulated for a different reason than yours did.

What the pooled trials found — in adults with HIV-associated lipodystrophy

Measure	Change
Visceral adipose tissue	−27.71 cm² (95% CI −38.37 to −17.06)
Hepatic fat	−4.28%
Trunk fat	−1.18 kg
Waist circumference	−1.61 cm
Limb fat	−0.22 kg
Lean body mass	+1.42 kg

The confidence interval on the visceral fat result is worth understanding rather than skipping. It means the pooled trials are consistent with a reduction as small as 17 cm² or as large as 38 cm², and the range does not cross zero. In plain terms: the effect is unlikely to be noise. It also does not tell you what any individual person experienced — averages describe groups, and groups contain people who responded strongly and people who did not respond at all.

What did not change

Subcutaneous fat — no significant change
BMI — no significant change
CD4+ cell count — no significant change

That middle line is the one most people skip past, and it is arguably the most interesting result in the analysis. Visceral fat fell substantially while BMI did not move. A bathroom scale would have shown nothing. Whatever happened in these trials, it was a change in where fat was distributed, not in how much the participants weighed.

The CD4+ result matters in this specific population: it indicates no measurable effect on immune cell counts in people living with HIV.

Why these numbers do not transfer to post-GLP-1 weight regain

HIV-associated lipodystrophy is a distinct metabolic condition. Certain antiretroviral regimens drive a characteristic redistribution of body fat — accumulation in the visceral compartment, loss in the limbs and face. It has a specific mechanism and a specific cause.

Weight regain after stopping a GLP-1 receptor agonist is a different process. Appetite regulation returns toward baseline, energy intake rises, and fat is regained in the pattern that person's physiology tends toward.

Same tissue. Different cause.

A drug studied in one condition is not thereby shown to work in another that superficially resembles it. It might. It might not. No randomized trial has asked the question, and until one does, applying these figures to a post-GLP-1 population is an assumption wearing the clothing of evidence.

This is the specific failure mode worth naming: a number that travels without its population. "Visceral fat down 27.71 cm²" is a fact. "Visceral fat down 27.71 cm² in adults with HIV-associated lipodystrophy" is the same fact with the part that determines whether it applies to you. The first version circulates far more widely than the second.

What tesamorelin is actually approved for

Tesamorelin received FDA approval in 2010 as Egrifta (NDA 022505, Theratechnologies) for the reduction of excess visceral abdominal fat in patients with HIV-associated lipodystrophy. A reformulated version, Egrifta WR, was approved on March 25, 2025.

The approved indication has never been broadened beyond that population.

Any use outside it is off-label. That is a description of regulatory status, not a recommendation for or against anything.

What the evidence does not tell us

Being precise about the gaps matters as much as reporting the findings.

No randomized evidence in non-HIV populations. Not weak evidence. None.
IGF-1 is unresolved. The published conclusion references improvement in IGF-1, but the analysis reports no IGF-1 figure. We are not quoting a number that the paper does not contain — and neither should anything else you read about this study.
Durability is unaddressed. The trials do not tell us what happens after treatment stops.
Clinical outcomes were not measured. Whether reducing visceral fat in this population reduces cardiovascular events is a separate question these trials were not designed to answer.

Reported adverse events across the pooled trials included arthralgia, myalgia, paresthesia, and injection-site reactions.

If you are reading this after a GLP-1

The reason this article exists in this form is that tesamorelin figures circulate in post-GLP-1 communities with the population quietly stripped out. A number without its population isn't evidence. It's a rumor with a decimal point.

What is actually established about weight regain after stopping a GLP-1: it is common, it is substantially driven by the return of appetite signaling, and the interventions with real evidence behind them are unglamorous — sustained protein intake, resistance training to defend lean mass, sleep, and continuity of care. None of that is a compound. All of it is boring. It is also what the evidence supports.

Body composition and body weight are not the same measurement. That much this analysis demonstrates clearly, and it is a genuinely useful idea to carry — the scale is a poor instrument for the thing most people actually care about.

The rest of it belongs to a population that is not yours.

Sources

Badran AS, Helal A, Shata KS, Ayesh H. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice, 2026. PMID 41545261. DOI 10.1016/j.orcp.2026.01.002
FDA prescribing information, Egrifta (tesamorelin), NDA 022505, Theratechnologies
FDA approval, Egrifta WR, March 25, 2025

PeptidesGPT publishes educational summaries of published research. This article describes what specific studies found in the populations they enrolled. It is not medical advice, does not recommend any compound, and is not a statement about what any individual should do. Decisions about treatment belong with a licensed clinician who knows your history.